14.19

7.25% -1.11

Contineum Therapeutics Inc (CTNM)

Overview News Price History Discussions Forecast

Contineum Therapeutics Inc stock is traded at $14.19, with a volume of 747.31K. It is down -7.25% in the last 24 hours and down -2.61% over the past month. Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Previous Close:

$15.30

Open:

$15.33

24h Volume:

747.31K

Relative Volume:

2.16

Market Cap:

$533.84M

Revenue:

$50.00M

Net Income/Loss:

$-58.44M

P/E Ratio:

-7.2669

EPS:

-1.9527

Net Cash Flow:

$-57.73M

1W Performance:

-5.65%

1M Performance:

-2.61%

6M Performance:

-1.73%

1Y Performance:

+95.45%

1-Day Range:

$14.10

$15.66

1-Week Range:

$14.10

$16.16

52-Week Range:

$7.20

$16.91

Contineum Therapeutics Inc Stock (CTNM) Company Profile

Name

Contineum Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(858) 333-5280

Address

3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

CTNM's Discussions on Twitter

Compare CTNM vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTNM Contineum Therapeutics Inc	14.19	563.56M	50.00M	-58.44M	-57.73M	-1.9527
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-13-25	Initiated	Leerink Partners	Outperform
Sep-25-25	Initiated	Leerink Partners	Outperform
Jun-20-25	Initiated	William Blair	Outperform
Oct-22-24	Initiated	Robert W. Baird	Outperform
Apr-30-24	Initiated	Morgan Stanley	Overweight
Apr-30-24	Initiated	RBC Capital Mkts	Outperform
Apr-30-24	Initiated	Stifel	Buy

View All

Contineum Therapeutics Inc Stock (CTNM) Latest News

04:41 AM

Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - marketbeat.com

04:41 AM

Aug 14, 2026

Contineum Therapeutics (NASDAQ:CTNM) Trading Down 4.9%What's Next? - marketbeat.com

Aug 14, 2026

Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing - Stock Titan

Aug 14, 2026

Aug 13, 2026

Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% HigherShould You Buy? - marketbeat.com

Aug 13, 2026

Aug 06, 2026

(CTNM) Risk Channels and Responsive Allocation - Stock Traders Daily

Aug 06, 2026

Aug 03, 2026

Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Nigeria

Aug 03, 2026

Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com - Investing.com Nigeria

Aug 03, 2026

Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise - Stock Titan

Aug 03, 2026

CTNM (CTNM) insider schedules 2,500-share stock sale after recent 10b5-1 trades - Stock Titan

Aug 03, 2026

CTNM (CTNM) insider Daniel Lorrain files to sell 9,520 common shares - Stock Titan

Aug 03, 2026

Contineum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 03, 2026

Aug 02, 2026

Perceptive Advisors LLC Has $16.40 Million Stake in Contineum Therapeutics, Inc. $CTNM - marketbeat.com

Aug 02, 2026

Aug 01, 2026

RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail

Aug 01, 2026

Jul 31, 2026

RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com

Jul 31, 2026

Jul 30, 2026

Contineum reports $15.2 million second quarter loss - Quiver Quantitative

Jul 30, 2026

Contineum Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView

Jul 30, 2026

Contineum Therapeutics reports Q2 2026 net loss $15.2M; cash and marketable securities $236.6M - TradingView

Jul 30, 2026

CTNM|Contineum Therapeutics Inc|Price:15.040|Chg%:-0.310 - TradingKey

Jul 30, 2026

Jul 28, 2026

Contineum Therapeutics, Inc. Revenue Breakdown – NASDAQ:CTNM - TradingView

Jul 28, 2026

Jul 27, 2026

BlackRock (CTNM stakeholder) reports 2.0M-share beneficial position in Therapeutics Inc - Stock Titan

Jul 27, 2026

CTNM|Contineum Therapeutics Inc|Price:15.390|Chg%:-0.510 - TradingKey

Jul 27, 2026

Jul 26, 2026